Vasopressin release by D-aspartic acid, morphine and prolyl-leucyl-glycinamide (PLG) in DI Brattleboro rats.

Koyuncuoğlu H, Berkman K, Hatipoğlu I, Sabuncu H

Pharmacology, biochemistry, and behavior1 Apr 1984Cited by 13 (Europe PMC)

PMID6145163DOI10.1016/0091-3057(84)90298-3PepBankPUB-06145163

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

3 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In homozygous Brattleboro rats, PLG significantly inhibited anterior brain L-asparaginase activity after injection.
In plain wordsIn rats, PLG reduced L-asparaginase activity in the anterior brain.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
DecreaseAnterior brain L-asparaginase activity
Study
ratn: not reported in source
Homozygous Brattleboro rats
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
6 mg/kgAs given in this study (rat).
Source sentences
Summary
Twenty min following the injections of 200 mg/kg D-aspartic acid, 20 mg/kg morphine, 200 mg/kg D-aspartic acid + 20 mg/kg morphine, 6 mg/kg prolyl-leucyl-glycinamide (PLG) and 6 mg/kg PLG + 20 mg/kg morphine the L-asparaginase activities of all three parts of the homozygous Brattleboro rat brains we…
Report a problemFND-0614516301
02AnimalAnimal study (in vivo)Mechanism
In homozygous Brattleboro rats, PLG significantly inhibited middle brain L-asparaginase activity after injection.
In plain wordsIn rats, PLG reduced L-asparaginase activity in the middle brain.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
DecreaseMiddle brain L-asparaginase activity
Study
ratn: not reported in source
Homozygous Brattleboro rats
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
6 mg/kgAs given in this study (rat).
Source sentences
Summary
Twenty min following the injections of 200 mg/kg D-aspartic acid, 20 mg/kg morphine, 200 mg/kg D-aspartic acid + 20 mg/kg morphine, 6 mg/kg prolyl-leucyl-glycinamide (PLG) and 6 mg/kg PLG + 20 mg/kg morphine the L-asparaginase activities of all three parts of the homozygous Brattleboro rat brains we…
Report a problemFND-0614516302
03AnimalAnimal study (in vivo)Mechanism
In homozygous Brattleboro rats, PLG significantly inhibited posterior brain L-asparaginase activity after injection.
In plain wordsIn rats, PLG reduced L-asparaginase activity in the posterior brain.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
DecreasePosterior brain L-asparaginase activity
Study
ratn: not reported in source
Homozygous Brattleboro rats
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
6 mg/kgAs given in this study (rat).
Source sentences
Summary
Twenty min following the injections of 200 mg/kg D-aspartic acid, 20 mg/kg morphine, 200 mg/kg D-aspartic acid + 20 mg/kg morphine, 6 mg/kg prolyl-leucyl-glycinamide (PLG) and 6 mg/kg PLG + 20 mg/kg morphine the L-asparaginase activities of all three parts of the homozygous Brattleboro rat brains we…
Report a problemFND-0614516303

Studies that did not test the peptide alone4

In this study, MIF-1 (Pro-Leu-Gly-NH2) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MIF-1 (Pro-Leu-Gly-NH2).

04AnimalNot a test of MIF-1 (Pro-Leu-Gly-NH2) aloneAnimal study (in vivo)Mechanism
In homozygous Brattleboro rats, PLG plus morphine significantly inhibited anterior brain L-asparaginase activity.
In plain wordsIn rats, PLG plus morphine reduced L-asparaginase activity in the anterior brain.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
DecreaseAnterior brain L-asparaginase activity with PLG and morphine
Study
ratn: not reported in source
Homozygous Brattleboro rats
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
Twenty min following the injections of 200 mg/kg D-aspartic acid, 20 mg/kg morphine, 200 mg/kg D-aspartic acid + 20 mg/kg morphine, 6 mg/kg prolyl-leucyl-glycinamide (PLG) and 6 mg/kg PLG + 20 mg/kg morphine the L-asparaginase activities of all three parts of the homozygous Brattleboro rat brains we…
In this study, MIF-1 (Pro-Leu-Gly-NH2) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MIF-1 (Pro-Leu-Gly-NH2).
Report a problemFND-0614516304
05AnimalNot a test of MIF-1 (Pro-Leu-Gly-NH2) aloneAnimal study (in vivo)Mechanism
In homozygous Brattleboro rats, PLG plus morphine significantly inhibited middle brain L-asparaginase activity.
In plain wordsIn rats, PLG plus morphine reduced L-asparaginase activity in the middle brain.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
DecreaseMiddle brain L-asparaginase activity with PLG and morphine
Study
ratn: not reported in source
Homozygous Brattleboro rats
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
Twenty min following the injections of 200 mg/kg D-aspartic acid, 20 mg/kg morphine, 200 mg/kg D-aspartic acid + 20 mg/kg morphine, 6 mg/kg prolyl-leucyl-glycinamide (PLG) and 6 mg/kg PLG + 20 mg/kg morphine the L-asparaginase activities of all three parts of the homozygous Brattleboro rat brains we…
In this study, MIF-1 (Pro-Leu-Gly-NH2) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MIF-1 (Pro-Leu-Gly-NH2).
Report a problemFND-0614516305
06AnimalNot a test of MIF-1 (Pro-Leu-Gly-NH2) aloneAnimal study (in vivo)Mechanism
In homozygous Brattleboro rats, PLG plus morphine significantly inhibited posterior brain L-asparaginase activity.
In plain wordsIn rats, PLG plus morphine reduced L-asparaginase activity in the posterior brain.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
DecreasePosterior brain L-asparaginase activity with PLG and morphine
Study
ratn: not reported in source
Homozygous Brattleboro rats
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
Twenty min following the injections of 200 mg/kg D-aspartic acid, 20 mg/kg morphine, 200 mg/kg D-aspartic acid + 20 mg/kg morphine, 6 mg/kg prolyl-leucyl-glycinamide (PLG) and 6 mg/kg PLG + 20 mg/kg morphine the L-asparaginase activities of all three parts of the homozygous Brattleboro rat brains we…
In this study, MIF-1 (Pro-Leu-Gly-NH2) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MIF-1 (Pro-Leu-Gly-NH2).
Report a problemFND-0614516306
07AnimalNot a test of MIF-1 (Pro-Leu-Gly-NH2) aloneAnimal study (in vivo)Mechanism
In homozygous Brattleboro rats, the listed treatments, including PLG and PLG plus morphine, produced significant amounts of plasma vasopressin.
In plain wordsIn rats, the listed treatments, including PLG and PLG plus morphine, produced significant amounts of vasopressin in plasma.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
IncreasePlasma vasopressin after the listed treatments
Study
ratn: not reported in source
Homozygous Brattleboro rats
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
The treatments applied to the homozygous Brattleboro rats caused the appearance of a significant amount vasopressin in the plasma.
1 context sentence(design, population, supporting numbers)
Summary · context
After having seen the suppressive effect of the drugs and their combinations used before the homozygous Brattleboro rats were given D-aspartic acid, morphine, D-aspartic acid + morphine, PLG and PLG + morphine for seven days. Then their plasma vasopressin levels were determined by RIA.
In this study, MIF-1 (Pro-Leu-Gly-NH2) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MIF-1 (Pro-Leu-Gly-NH2).
Report a problemFND-0614516307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.